Compounds for the treatment of HIV
Granted: June 15, 2021
Patent Number:
11034668
The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.
Phosphatidylinositol 3-kinase inhibitors
Granted: June 1, 2021
Patent Number:
11021467
The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein n, W, A?, B?, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or…
Methods for treating arenaviridae and coronaviridae virus infections
Granted: May 18, 2021
Patent Number:
11007208
Provided are methods for treating Arenaviridae and Coronaviridae virus infections by administering nucleosides and prodrugs thereof, of Formula I: wherein the 1? position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections.
Processes and intermediates for the preparation of 1?-substituted carba-nucleoside analogs
Granted: April 27, 2021
Patent Number:
10988498
Provided are processes and intermediates for the syntheses of nucleosides of pyrrolo[1,2-f][1,2,4]triazinyl and imidazo[1,2-f][1,2,4]triazinyl heterocycles of Formula I.
MCL-1 inhibitors
Granted: April 27, 2021
Patent Number:
10988451
The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
FXR (NR1H4) modulating compounds
Granted: April 20, 2021
Patent Number:
10981881
The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
Combination therapy comprising an ACC inhibitor
Granted: April 20, 2021
Patent Number:
10980810
The present disclosure provides methods and compositions for treating, stabilizing or lessening the severity or progression of a non-alcoholic fatty liver disease.
Synthesis of polycyclic-carbamoylpyridone compounds
Granted: April 13, 2021
Patent Number:
10975096
Methods of making compounds of Formula I are disclosed:
Process methods for phosphatidylinositol 3-kinase inhibitors
Granted: March 23, 2021
Patent Number:
10954199
A process for the synthesis of quinazolinone containing compounds which may be useful for the treatment of cancer, is hereby disclosed. In addition, compound intermediates relating to these processes are also disclosed.
Cot modulators and methods of use thereof
Granted: March 16, 2021
Patent Number:
10947259
The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.
Solid forms of an ASK1 inhibitor
Granted: March 16, 2021
Patent Number:
10946004
Crystalline forms of 5-(4-cyclopropyl-1H-imidazol-1-yl)-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-2-fluoro-4-methylbenzamide (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the crystalline forms.
Method of purifying an antibody
Granted: March 9, 2021
Patent Number:
10941178
The present disclosure relates generally to methods of producing, processing, or purifying antibodies. The present disclosure also relates to methods of producing, processing, or purifying a target antibody from cell cultures to remove host cell proteins.
2?-substituted carba-nucleoside analogs for antiviral treatment
Granted: March 9, 2021
Patent Number:
10941177
Provided are compounds of Formula I, as well as pharmaceutical compositions containing compounds of Formula I and methods for treating Orthomyxoviridae virus infections by administering these compounds. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections.
PD-1/PD-L1 inhibitors
Granted: January 26, 2021
Patent Number:
10899735
Compounds and methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
Multispecific antibodies that target HIV GP120 and CD3
Granted: January 5, 2021
Patent Number:
10882907
Multispecific antibodies (e.g., bispecific antibodies) that bind to HIV gp120 and CD3 are disclosed. Also disclosed are methods of using such antibodies to treat or prevent HIV infection.
Human immunodeficiency virus neutralizing antibodies
Granted: January 5, 2021
Patent Number:
10882898
The present invention provides novel anti-HIV antibodies with improved therapeutic properties, related pharmaceutical compositions, and methods of use thereof.
4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
Granted: January 5, 2021
Patent Number:
10882851
This invention provides quinazoline derivatives represented by the structural formula: (I); wherein: R2 is hydrogen, NR?R?, C1-7 alkyl, arylC1-7 alkyl or C3-10 cycloalkyl; R4 is amino, C1-7 alkyl, C2-7 alkenyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, aryl, heterocyclic, arylalkyl, heterocyclic-substituted C1-7 alkyl or C3-10 cycloalkyl-C1-7 alkyl; R5 is hydrogen or C1-7 alkyl, or R5 and R4 together with the nitrogen atom to which they are attached form a heterocyclic ring; Y is a single…
Pyrrolo[1,2-B]pyridazine derivatives
Granted: December 29, 2020
Patent Number:
10875866
A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof, wherein the variable substituents are disclosed herein.
Substituted pyrrolizine compounds and uses thereof
Granted: December 29, 2020
Patent Number:
10874640
This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
Antibodies and fragments thereof that bind hepatitis B virus protein X
Granted: December 22, 2020
Patent Number:
10870691
Provided herein are, inter alia, antibodies, antigen-binding antibody fragments, cells, polynucleotides, compositions, kits, and methods relating to the detection of HBV protein X (HBx), e.g., in vitro and in vivo. Included are antibodies and fragments thereof that bind HBx, as well as kits, cells, and compositions comprising such antibodies and fragments.
